ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pimasertib

Also written as “Pimasertib”, “MSC1936369B” and “Pimasertib Capsule (Part A)”.

Its studies are mostly in Neoplasms · Melanoma · Neoplasm Metastasis · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 3 companies.

Drug pagePimasertib: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Aug 11, 200913 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germanyits history only110 open or runningphase 2since Aug 11, 2009Aug 11, 2009none ahead
Day One Biopharmaceuticals10 open or runningphase 1since Jul 3, 2025Jul 3, 2025none ahead
Sanofiits history only10 open or runningphase 1since May 16, 2011May 16, 2011none ahead

Also a collaborator on its studies: Merck Serono S.A., Geneva and Merck Serono Co., Ltd., Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Day One Biopharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 3, 2025First study: phase 1 study in MelanomaFirst studyNCT07121829 · 44 enrolled · United States, Canada

TargetBeta

“An orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) ”NCIt, by rule
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

The one study Day One Biopharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07121829Melanoma · United States, Canada1TerminatedDec 18, 202444

How it is read

Names in the registry

  • “Pimasertib”, 16 entries
  • “MSC1936369B”, 5 entries
  • “Pimasertib Capsule (Part A)”, 2 entries
  • “Pimasertib Tablet (Part A)”, 2 entries
  • “MSC1936369B (pimasertib)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.